Recently, the small‐molecule tyrosine kinase inhibitor (TKI) tucatinib was proven efficacious in heavily pretreated HER2+ BC patients with brain metastasis, improving both progression‐free survival (PFS) and overall survival (OS) in the HER2CLIMB trial.13 The gene discussed is ERBB2; the disease is breast cancer.